Eli Lilly To Buy Mass. Biopharmaceutical Biz For Up To $300M
Pharmaceutical giant Eli Lilly & Co. on Thursday announced it has agreed to buy Cambridge, Massachusetts-based biopharmaceutical company Sigilon Therapeutics Inc. in a deal that could be worth upward of $300...To view the full article, register now.
Already a subscriber? Click here to view full article